EGFR and non-small cell lung carcinoma: These results together indicate that EGFR-TKIs, particularly osimertinib, suppress MEK/ERK signaling, decrease DR4 expression and induce apoptosis primarily in the sensitive EGFRm NSCLC cell lines.